Clinical trial

Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC

NCT03184090

Study summary

ClinicalTrials.gov

Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Palbociclib Normalized identity: palbociclib View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Endocrine therapy (non IMP) Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-06-28

PhasePHASE2

Conditions

Metastatic Breast Cancerunresolved

Interventions

PalbociclibDRUG · verified · RxNorm: palbociclib

Endocrine therapy (non IMP)DRUG

Sponsors & collaborators

MedSIRlead sponsor

Mapped research locations

ValenciaSpain3 BarcelonaSpain2 MadridSpain1 MilanItaly1 SevilleSpain1 A CoruñaSpain1 CórdobaSpain1 L'Hospitalet de LlobregatBarcelona, Spain1 BadalonaBarcelona, Spain1 UdineItaly1 CastellonSpain1 ReusSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03184090 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.